Allspring Global Investments Holdings LLC Has $62.80 Million Stock Position in Haemonetics Co. (NYSE:HAE)

Allspring Global Investments Holdings LLC raised its position in Haemonetics Co. (NYSE:HAE - Free Report) by 0.7% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 801,049 shares of the medical instruments supplier's stock after buying an additional 5,668 shares during the quarter. Allspring Global Investments Holdings LLC owned 1.60% of Haemonetics worth $62,802,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently modified their holdings of the company. Nisa Investment Advisors LLC grew its stake in shares of Haemonetics by 124.2% in the third quarter. Nisa Investment Advisors LLC now owns 1,141 shares of the medical instruments supplier's stock valued at $92,000 after acquiring an additional 632 shares in the last quarter. KBC Group NV grew its position in shares of Haemonetics by 54.6% during the 4th quarter. KBC Group NV now owns 2,016 shares of the medical instruments supplier's stock worth $157,000 after purchasing an additional 712 shares in the last quarter. iSAM Funds UK Ltd bought a new position in shares of Haemonetics during the third quarter worth approximately $204,000. CWC Advisors LLC. acquired a new stake in shares of Haemonetics in the third quarter valued at approximately $231,000. Finally, Versor Investments LP boosted its stake in shares of Haemonetics by 9.1% in the third quarter. Versor Investments LP now owns 3,600 shares of the medical instruments supplier's stock valued at $289,000 after buying an additional 300 shares during the period. Institutional investors and hedge funds own 99.67% of the company's stock.

Haemonetics Price Performance

NYSE:HAE traded up $0.18 on Monday, hitting $62.47. The company had a trading volume of 1,333,274 shares, compared to its average volume of 959,630. Haemonetics Co. has a 52 week low of $58.80 and a 52 week high of $97.97. The stock has a market capitalization of $3.14 billion, a price-to-earnings ratio of 24.59, a PEG ratio of 0.98 and a beta of 0.39. The company has a current ratio of 3.97, a quick ratio of 2.09 and a debt-to-equity ratio of 1.35. The firm has a 50 day moving average of $74.18 and a two-hundred day moving average of $77.22.

Haemonetics (NYSE:HAE - Get Free Report) last announced its quarterly earnings results on Thursday, February 6th. The medical instruments supplier reported $1.19 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.20 by ($0.01). Haemonetics had a net margin of 9.47% and a return on equity of 23.66%. On average, research analysts anticipate that Haemonetics Co. will post 4.59 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research firms have commented on HAE. JMP Securities lowered their price objective on Haemonetics from $125.00 to $100.00 and set a "market outperform" rating on the stock in a research note on Friday, February 7th. StockNews.com cut Haemonetics from a "buy" rating to a "hold" rating in a research report on Saturday. Barrington Research dropped their price target on Haemonetics from $108.00 to $95.00 and set an "outperform" rating for the company in a research note on Friday, February 7th. JPMorgan Chase & Co. started coverage on shares of Haemonetics in a report on Friday, December 6th. They issued an "overweight" rating and a $116.00 target price on the stock. Finally, Raymond James reaffirmed a "strong-buy" rating and set a $115.00 price target (down previously from $120.00) on shares of Haemonetics in a report on Friday, February 7th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $101.67.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.